IBCL-461 A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+ Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States
Clinical Lymphoma Myeloma and Leukemia（2024）
Key words
IBCL,tazemetostat,relapsed/refractory follicular lymphoma,R/R FL,budget impact,cost saving
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined